PR Yu @PRYU

Proud to share that @YuGalaxy has closed $90M for Fund III, bringing AUM to $500M. As a solo GP, I’m committed to backing mission-driven founders committed to solving the world’s hardest problems in healthcare, AI, defense & automation. Conviction. Speed. Measurable Impact. 🚀 #VentureCapital #SocialImpact Yu Galaxy Secures $90M Raise to Surpass $500M AUM, Redefining How Venture Capital Invests in Global Challenges - businesswire.com/news/home/2025…

Thrilled to announce that our portfolio company, Capstan Medical , has secured $110M in an oversubscribed Series C round! Heart disease remains the world’s #1 killer, claiming a life every 30 seconds in the US alone. Traditional treatments often deter patients due to their invasive nature – requiring hours of open-heart surgery with extended recovery periods and substantial associated risks. Enter Capstan's revolutionary robotic surgical platform: a minimally invasive solution that can treat heart disease without opening the chest or stopping the heart. What once took hours could now be completed in under 60 minutes, with significantly reduced recovery time and complications. The innovation stems from a world-class team led by Maggie Nixon and Dan Wallace, who were instrumental in developing the da Vinci Surgical System at Intuitive Surgical (~$200B market cap, also an investor in Capstan). What truly energizes us about this investment goes far beyond the tremendous market opportunity – it's about transforming cardiac care and giving millions of patients a better chance at life. Congratulations to the entire Capstan team! We're honored to be part of your journey. Capstan Medical Secures $110M to Bring First-of-its-Kind Robotics Technology to Heart Disease Patients prn.to/3DdKa15

Congratulations to our portfolio company, @Inquismedical, on their oversubscribed $40M funding round! 🎉 Inquis was founded by our longtime friends and partners, Vahid Saadat and Mojgan Saadat, and we’re incredibly proud to have supported them from the very beginning, investing in every round along the way. Each year, nearly 1 million people in the U.S. suffer from blood clots (venous thromboembolism, or VTE), leading to approximately 100,000 deaths. Inquis is tackling this urgent healthcare challenge with its innovative catheter devices, featuring proprietary FDA-approved tissue-sensing and blood return technologies. These devices enable efficient clot-removal procedures and help minimize blood loss. The company is also nearing completion of patient enrollment for a pivotal trial focused on pulmonary embolism, a major step forward in their mission to improve patient outcomes. We're excited for what’s to come! businesswire.com/news/home/2024…

You may have heard that the University of Colorado Boulder’s football team, under Coach Prime, is one of the hottest programs and has sold the most expensive tickets in the nation last season, averaging over $500 each. But did you know that CU also ranks in the top five nationwide for startup spinoffs?

Check out my newly published article: Be Bolder: What leaders can learn from CU Boulder's successes in research, innovation, and football. fastcompany.com/91203304/be-bo…

It's the exciting journal club time! Today, I'm proudly presenting you the paper just published by the exceptional team at our portfolio company, Aqtual, Inc.: Extracting regulatory active chromatin footprint from cell-free DNA. Abstract below, and the whole paper is downloadable. Cell-free DNA (cfDNA) has emerged as a pivotal player in precision medicine, revolutionizing the diagnostic and therapeutic landscape. While its clinical applications have significantly increased in recent years, current cfDNA assays have limited ability to identify the active transcriptional programs that govern complex disease phenotypes and capture the heterogeneity of the disease. To address these limitations, we have developed a non-invasive platform to enrich and examine the active chromatin fragments (cfDNAac) in peripheral blood. The deconvolution of the cfDNAac signal from traditional nucleosomal chromatin fragments (cfDNAnuc) yields a catalog of features linking these circulating chromatin signals in blood to specific regulatory elements across the genome, including enhancers, promoters, and highly transcribed genes, mirroring the epigenetic data from the ENCODE project. Notably, these cfDNAac counts correlate strongly with RNA polymerase II activity and exhibit distinct expression patterns for known circadian genes. Additionally, cfDNAac signals across gene bodies and promoters show strong correlations with whole blood gene expression levels defined by GTEx. This study illustrates the utility of cfDNAac analysis for investigating epigenomics and gene expression, underscoring its potential for a wide range of clinical applications in precision medicine. nature.com/articles/s4200…

According to cloud risk firm @Parametrix, the direct losses from the global IT systems outage caused by the incident are estimated at $5.4 billion. Thanks to InsightFinder’s early detection, its clients were able to significantly reduce their losses. insightfinder.com/blog/how-insig… @yugalaxyvc

CrowdStrike’s software update went live at 4:09 am UTC on July 19, and InsightFinder identified anomaly incidents among affected #IT systems from 4:27 am—an hour before @CrowdStrike recognized and addressed the problem.

Here's a story of how AI has helped save the day: During the recent global IT outage caused by #CrowdStrike, our portfolio company @insightfinders' #AI tools played a pivotal role for its clients in mitigating the impact.

Yu Galaxy is dedicated to investing in healthcare technology that transforms patient care and outcomes. We support startups with groundbreaking ideas to improve global health. Join us in making a difference. 🌟 Visit our website for more information yugalaxy.com

A strong team is the backbone of any successful startup. Surround yourself with talented and motivated individuals who share your vision. At Yu Galaxy, we help startups build teams that drive innovation and growth. 🚀 Ready to scale? yugalaxy.com

At Yu Galaxy, we're leveraging technology to tackle critical issues in healthcare, energy, digital transformation, and automation. Our mission? To make a profound and positive impact on society. Let's innovate for a better future! 💡 Learn more here yugalaxy.com

Every major leap in economic growth has been fueled by innovation, from the Industrial Revolution to the Digital Age. 🌏 What’s next on the horizon? #Innovation

@yugalaxy ...while our AI and automation firms have introduced solutions that significantly boost societal efficiency. yugalaxy.com

@yugalaxy Yet more thrilling than the financial milestones are the tangible impacts our portfolio companies are making globally: our healthcare enterprises have saved many lives and enhanced quality of life for even more.

In the first half of 2024, @YuGalaxy portfolio companies have secured approximately $200 million in new funding.

A strong team is the backbone of any successful startup. Surround yourself with talented and motivated individuals who share your vision. At Yu Galaxy, we help startups build teams that drive innovation and growth. 🚀 Ready to scale? yugalaxy.com #YuGalaxy

Startups are the engine of job creation, generating twice as many jobs as established companies. At Yu Galaxy, we support startups that drive economic growth and innovation. 💡 Join us in innovation to unlock new opportunities and drive growth! buff.ly/3PTooDp

Yu Galaxy is dedicated to investing in healthcare technology that transforms patient care and outcomes. We support startups with groundbreaking ideas to improve global health. 🌟 Visit our website for more information buff.ly/3PTooDp #YuGalaxy #HealthcareInnovation

@conchalabs Check them out at conchalabs.com.

@conchalabs What’s remarkable is that these hearing aids can be ordered online and set up at home in under 10 minutes, a stark contrast to the six-month timeline and multiple doctor visits typically required for traditional products. This isn’t merely about hearing aids; it’s AI at its best.

As a venture capitalist and entrepreneur, few things are as exhilarating as witnessing our products transform the lives of both those we know and countless others we may never meet.